Clinical Trials Browser

Terminated × NIH × cediranib × Clear all

NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

NCT00527124 2018-08-09

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

57 enrolled 12 charts

Prostatic Neoplasms

NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Phase 2 Terminated

26 enrolled 8 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01229111 2017-03-29

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Phase 2 Terminated

14 enrolled 11 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT00427973 2016-10-31

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Phase 2 Terminated

17 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00303862 2014-05-21

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Phase 2 Terminated

10 enrolled 5 charts

Carcinoma, Renal Cell

NCT00937482 2013-03-08

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 1 Terminated

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Breast Neoplasms, Male